<DOC>
	<DOCNO>NCT00530712</DOCNO>
	<brief_summary>This multi-center , non-randomized , single arm study compare PTA primary stenting use single PROTÉGÉ® EverFlex™ stent performance goal PTA alone treatment atherosclerotic superficial femoral artery ( SFA ) proximal popliteal lesion .</brief_summary>
	<brief_title>Safety Effectiveness Study EverFlex Stent Treat Symptomatic Femoral-popliteal Atherosclerosis</brief_title>
	<detailed_description />
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Menthol</mesh_term>
	<criteria>Stenotic , restenotic ( PTA adjunct therapy , include stent stent graft ) occlude lesion ( ) locate native superficial femoral artery superficial femoral proximal popliteal artery . Symptomatic femoralpopliteal atherosclerosis . Willing comply followup evaluation specify time . Provides write informed consent prior enrollment study . Previously implant stent ( ) stent graft ( ) target vessel . Planned use device angioplasty balloon procedure . Received endovascular treatment target lesion ( except stents/stent graft ) within six month index procedure . Life expectancy le 12 month . Symptomatic femoral disease opposite limb .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>SFA</keyword>
	<keyword>Popliteal</keyword>
	<keyword>Stent</keyword>
	<keyword>EverFlex</keyword>
</DOC>